Aurinia Pharmaceuticals (AUPH) Share-based Compensation (2020 - 2026)
Aurinia Pharmaceuticals (AUPH) posted Share-based Compensation of -$866000.0 for Q1 2026, down 112.87% on a QoQ basis from $6.7 million in Q4 2025, and down 109.69% year-over-year from $8.9 million in Q1 2025.
Aurinia Pharmaceuticals (AUPH) Share-based Compensation (2020 - 2026) Analysis & Trends
Aurinia Pharmaceuticals' Share-based Compensation history runs 7 years deep, the most recent figure standing at -$866000.0 for Q1 2026.
- Quarterly Share-based Compensation fell 109.69% year-over-year to -$866000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (down 86.07% YoY) and the FY2025 annual result came in at $14.7 million, down 53.54% from the prior year.
- Share-based Compensation was -$866000.0 for Q1 2026 at Aurinia Pharmaceuticals, down from $6.7 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $25.7 million in Q4 2024 and bottomed at -$31.3 million in Q4 2023.
- A 5-year average of $3.2 million and a median of $6.7 million in 2025 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 383.99% — and 2024, when it jumped 182.22%.
- Aurinia Pharmaceuticals' Share-based Compensation stood at -$24.4 million in 2022, then fell by 28.35% to -$31.3 million in 2023, then soared by 182.22% to $25.7 million in 2024, then sank by 73.83% to $6.7 million in 2025, then slumped by 112.87% to -$866000.0 in 2026.
- Business Quant data shows AUPH's Share-based Compensation at -$866000.0 in Q1 2026, $6.7 million in Q4 2025, and $5.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Aurinia Pharmaceuticals | 2.02 Bn | 1.64 Bn | 71.20 Mn | -866,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -866,000.00 |
| Mar 31, 2026 | -866,000.00 |
| Dec 31, 2025 | 6.73 Mn |
| Dec 31, 2025 | 6.73 Mn |
| Sep 30, 2025 | 5.92 Mn |
| Sep 30, 2025 | 5.92 Mn |
| Jun 30, 2025 | -6.90 Mn |
| Jun 30, 2025 | -6.90 Mn |
| Mar 31, 2025 | 8.93 Mn |
| Mar 31, 2025 | 8.93 Mn |
| Dec 31, 2024 | 25.70 Mn |
| Dec 31, 2024 | 25.70 Mn |
| Sep 30, 2024 | -8.43 Mn |
| Sep 30, 2024 | -8.43 Mn |
| Jun 30, 2024 | 8.83 Mn |
| Jun 30, 2024 | 8.83 Mn |
| Mar 31, 2024 | 5.50 Mn |
| Mar 31, 2024 | 5.50 Mn |
| Dec 31, 2023 | -31.26 Mn |
| Dec 31, 2023 | -31.26 Mn |